Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies)

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 20, Issue 4, 1999, Pages 394-402

  Agapé, Philippe ^f   Copin, Marie Christine ^a   Cavrois, Marielle ^e   Panelatti, Gérard ^f   Plumelle, Yves ^f   Ossondo Landeau, Marlène ^f   Quist, Danièle ^b   Grossat, Nathalie ^c   Gosselin, Bernard ^a   Fenaux, Pierre ^a   Wattel, Eric ^a,d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^c CHU Fort de France   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e UNIVERSITY OF MARYLAND   (United States)

^f CHU ^*

Author keywords

Adult T cell leukemia lymphoma; HTLV 1; Non Hodgkin's lymphoma; P53; Strongyloidiasis

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN P53;

ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG RESPONSE; ENDEMIC DISEASE; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEROLOGY; STRONGYLOIDIASIS; SURVIVAL RATE; T CELL LEUKEMIA; T CELL LYMPHOMA;

EID: 0033002897     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199904010-00011     Document Type: Article

References (68)

1. Poiesz BJ, Ruscetti FW, Fazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7145-9.
2. Uchiyama T, Yodoi J, Sagawa T, Takatsuki K, Ushino H. Adult T-cell leukemia: clinical and hematologic feature of 16 cases. Blood 1977;50:481-92.
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-10.
4. Takatsuki K, Yamagushi K, Kawano F, et al. Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res 1985;45:4644-5.
5. Shimoyama M, members of The Lymphoma Study Group. Diagnosic criteria and classification of clinical subtypes of adult T-cell leukaemia/lymphoma. A report from the lymphoma study group (1984-1987). Br J Haematol 1991;79:428-39.
6. Plumelle Y, Pascaline N, Nguyen D, et al. Adult T-cell leukemia lymphoma: a clinicopathologic study of twenty-six patients from Martinique. Hematol Pathol 1993;7:251-62.
7. Blattner W. Human T-Lymphotropic viruses and diseases of long latency. Ann Intern Med 1989;111:4-5.
8. Nakada K, Koharura M, Komoda H, Hinuma Y. High incidence of HTLV-I antibody in carriers of Strongyloides stercoralis. Lancet 1984;1:633.
9. Nakada K, Yamagushi K, Furugen S, et al. Monoclonal integration of HTLV-I proviral DNA in patients with Strongyloides. Int J Cancer 1987;40:145-8.
10. Patey O, Gessain A, Breuil J, et al. Seven years of recurrent severe strongyloidiasis in an HTLV-1-infected man who developed adult T-cell leukaemia. AIDS 1992;6:575-9.
11. Plumelle Y, Gonin C, Edouard A, et al. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am J Clin Pathol 1997;107:81-7.
12. Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994;169:692-6.
13. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783-4.
14. Cesarman E, Chadburn A, Innghirami G, Giadano G, Knowles D. Structural and functional analysis of oncogenes and tumor suppressor genes in ATLL shows frequent P53 mutations. Blood 1992; 80:3205-216.
15. Sakashita A, Hattori T, Miller W, et al. Mutations of P53 in ATL. Blood 1992;79:477-80.
16. Nishimara S, Asou N, Susushima H, et al. P53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T-cell leukemia. Leukemia 1995;9:598-604.
17. Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 1993;8:3029-36.
18. Fonseca L, Yonemura Y, De Aretxabala X, Yamaguchi A, Miwa K, Miyazaki I. p53 detection as a prognostic factor in early gastric cancer. Oncology 1994;51:485-90.
19. Klemi PJ, Pylkkänen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76: 1201-8.
20. Newcomb EW. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995;17: 211-21.
21. Nakai H, Misawa S. Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Leuk Lymphoma 1995;19:213-21.
22. Wattel E, Preudhomme C, Hecquet B, et al. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
23. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337: 529-33.
24. Knowles DM, Chadburn AC, Inghirami G. Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms. In Knowles DM, ed. Neoplastic hematopathology. Baltimore: Williams & Wilkins, 1992:73-167.
25. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international study group. Blood 1994;84:1361-92.
26. Jacquemier J, Molès JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies. comparison of staining and PCR-SSCP results. Br J Cancer 1994;69:846-52.
27. Detourmignies L, Copin MC, Morel P, et al. P53 overexpression in diffuse large cell lymphoma (DLCL) and its prognostic value by multiparameter analysis. Blood 1996;88(Suppl 1):383a.
28. Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-I infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene 1996;12:2419-23.
29. Cavrois M, Wain-Hobson S, Wattel E. Stochastic events in the amplification of HTLV-I integration sites by linker-mediated PCR. Res Virol 1995;146:179-84.
30. Cavrois M, Wain-Hobson S, Gessain A, Plumelle Y, Wattel E. Adult T-cell leukemia/lymphoma on a background of clonally expanding HTLV-I positive cells. Blood 1996;88:4646-50.
31. Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993;104:119-22.
32. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
33. Cox DR. Regression models and life-tables [with discussion]. JR Stat Soc B 1972;34:187-202.
34. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin s lymphomas. Cancer Treat Rep 1977;61: 1023-7.
35. Takimoto Y, Tanaka H, Tanabe O, Kuramoto A, Sasaki N, Nanba K. A patient with anaplastic large cell lymphoma (Ki-1 lymphoma) showing clonal integration of HTLV-I proviral DNA. Leukemia 1994;8:507-9.
36. Detmar M, Pauli G, Anagnostopoulos I, et al. A case of classical mycosis fungoides associated with human T-cell lymphotropic virus type I. Br J Dermatol 1991;124:198-202.
37. Xialong J, Weihua I. Malignant lymphomas in Beijing. J Environ Pathol Toxicol Oncol 1992;11:327-9.
38. Su IJ, Shih LY, Kadin ME, Dunn P, Hsu SM. Pathologic and immunologic characterization of malignant lymphoma in Taiwan. Am J Clin Pathol 1985;84:715-23.
39. Tajima K, Tominaga S, Kuroishi T, Shimizu H, Suchi T. Geographical features and epidemiological approach to endemic T-cell lymphoma in Japan. Jpn J Clin Oncol 1979;9:495-504.
40. Gibbs WN, Lofters WS, Campbell M, et al. Non-Hodgkin's lymphoma in Jamaica and its relation to adult T-cell leukemialymphoma. Ann Intern Med 1987;106:361-8.
41. Coiffier B, Brousse N, Peuchmaur M, et al., for the GELA (Groupe d'Etude des Lymphomes Agressifs). Peripheral T-cell lymphoma have a worse prognosis than B-cell lymphomas: a retrospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990;1:45-50.
42. Giselbrecht C, Gaulard Ph, Lepage B, et al., for the GELA (Groupe d'Étude des Lymphomes Agressifs). Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1996;88(Suppl 1):293a.
43. Berard CW, Greene MH, Jaffe ES, Magrath I, Ziegler J. A multidisciplinary approach to non-Hodgkin s lymphomas. Ann Intern Med 1981;94:218-35.
44. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996;88:2385-409.
45. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991;9:211-19.
46. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 1994;83:1165-73.
47. Gessain A, Jouanelle A, Escarmant P, Calender A, Shaffar-Deshayes L, de Thé G. HTLV-I antibodies in patients with non-Hodgkin's lymphomas in Martinique. Lancet 1984;1:1183-4.
48. Sakamoto Y, Kawachi Y, Uchida T, et al. Adult T-cell leukaemia/ lymphoma featuring a large granular lymphocyte leukemia morphologically. Br J Haematol 1994;86:383-5.
49. Shimamoto Y, Yamaguschi M. HTLV-I induced extranodal lymphomas. Leuk Lymphoma 1992;7:37-45.
50. Manns A, Cleghorn FR, Falk RT, et al. Role of HTLV-I in development of non-Hodgkin's lymphoma in Jamaica and Trinidad and Tobago. Lancet 1993;342:1447-50.
51. Shimoyama M. Chemotherapy of ATL: adult T-cell leukemia. Oxford: Medical Publications, 1994:221-37.
52. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744-8.
53. Hermine O, Bouscary, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995;332:1749-51.
54. Matsumoto T, Miike T, Mizoguchi K, et al. Decreased serum levels of IgE and IgE-binding factors in individuals infected with HTLV-1. Clin Exp Immunol 1990;81:207-11.
55. Newton RC, Limpuangthip P, Greenberg S, Gam A, Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med 1992;92:202-8.
56. Yamada Y, Murata K, Kamihira S, et al. Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 1991;67:2605-9.
57. Kamihira S, Sohda H, Atogami S, et al. Phenotypic diversity and prognosis of adult T-cell leukemia. Leuk Res 1992;16:435-41.
58. Sadamori N, Ikeda S, Yamaguchi K, et al. Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. Leuk Res 1991;15:99-103.
59. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994;73:2753-8.
60. Sugito S, Yamato K, Sameshima Y, Yokota J, Yano S, Miyoshi I. Adult T-cell leukemia:structures and expression of the p53 gene. Int J Cancer 1991;49:880-5.
61. Nagai H, Kinoshita T, Imamura J, et al. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 1991;82:1421-7.
62. Yamato K, Oka T, Hiroi M, et al. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-1-infected cells. Jpn J Cancer Res 1993;84:4-8.
63. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
64. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
65. Su IJ, Chang IC, Cheng AL. Expression of growth-related genes and drug-resistance genes in HTLV-1-positive and HTLV-1-negative post-thymic T-cell malignancies. Ann Oncol 1991;2: 151-5.
66. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990;76:2065-71.
67. Arany I, Fleischmann CM, Tyring SK, Fleischmann WR. Interferon regulates expression of mda-6/WAF1/CIP1 and cyclindependent kinases independently from p53 in B16 murine melanoma cells. Biochem Biophys Res Commun 1997;233:678-80.
68. Ossina NK, Cannas A, Powers VC, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272:16351-7.